QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

MLTX

QT80MoonLake Immunotherapeutics
NASDAQ·Healthcare·Biotechnology·Switzerland
Latest market price
19.21
+0.02+0.10%
OverviewShort InterestFilings
MLTXQT80MoonLake Immunotherapeutics·NASDAQ
OverviewShort InterestFilings
19.21+0.10%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand-
Perf Week8.23%
Market Cap1.41BForward P/E-EPS next Y-3.64Insider Trans-Shs Float-Perf Month17.35%
Enterprise Value1.21BPEG0.12EPS next Q-0.93Inst Own-Short Float-Perf Quarter15.17%
Income-265583736.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y25.23%
Sales-P/B5.38EPS next Y4.97%ROA-64.21%Short Interest-Perf YTD45.75%
Book/sh-P/C-EPS next 5Y-ROE-85.61%52W High62.76 -69.39%Perf Year-55.33%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-75.28%52W Low5.95 222.86%Perf 3Y-
Dividend Est.-EV/EBITDA-4.94Sales past 3/5Y-Gross Margin0.00%Volatility3.72% 3.31%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-104.76%Oper. Margin0.00%ATR (14)0.97Perf 10Y-
Dividend Ex-Date-Quick Ratio8.60Sales Y/Y TTM-Profit Margin0.00%RSI (14)58.60Recom2.45
Dividend Gr. 3/5Y-Current Ratio8.60EPS Q/Q-55.56%SMA204.11%Beta1.22Target Price28.50
Payout0.00%Debt/Eq0.40Sales Q/Q-SMA507.35%Rel Volume0.88Prev Close19.19
Employees100LT Debt/Eq0.24EarningsAug 04SMA2002.08%Avg Volume874.15KPrice19.21
IPO DateOct 20, 2020Option/ShortYes / YesEPS/Sales Surpr.-7.69% -Net Debt/EBITDA0.80Volume773,144Change0.10%
Analyst Ratings
DateActionAnalystRatingTarget
May-11-26ReiteratedH.C. Wainwright$40 → $45
Mar-23-26UpgradeWolfe ResearchUnderperform → Outperform
Mar-19-26UpgradeRothschild & CoNeutral → Buy
Feb-24-26ReiteratedOppenheimerOutperform$30 → $35
Jan-15-26DowngradeGoldman SachsNeutral → Sell$10
Jan-09-26ReiteratedH.C. Wainwright$26 → $32
Jan-09-26ReiteratedUBS$45 → $24
Jan-09-26UpgradeBTIGNeutral → Buy
Jan-08-26ReiteratedUBS$12 → $45
Nov-21-25ReiteratedH.C. Wainwright$30 → $26
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A300
Gross Profit-300
Selling, General and Administrative Excl. Other423022
Research and Development20311332
Other Operating Expense-300
Operating Income-245-143-54
Interest Expense700
Unusual Expense
———
Non-Operating Income (Expense)-22-22-10
Net Income Before Taxes-230-121-44
Income Taxes100
Consolidated Net Income-227-119-36
Net Income From Continuing Operations-230-121-44
Net Income-227-119-36
EPS (Recurring)-3.53-1.89-0.73
EPS (Basic, Before Extraordinaries)-3.53-1.89-0.73
EPS (Diluted)-3.53-1.89-0.73
EBITDA-220-120-44
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding646349
Market Capitalization844——
Operating Lease Expense
———
Insider Trading Volume
$20.80$19.71$18.63$17.54$16.45● Close Price0.00M15.74M31.48M47.22M62.96MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Reich KristianChief Scientific OfficerJun 17 '26Sale19.4350,000971,5002,824,551Jun 17 12:00 AM
Reich KristianChief Scientific OfficerJun 16 '26Sale18.7050,000935,0002,874,551Jun 17 12:00 AM
Reich KristianChief Scientific OfficerJun 15 '26Sale18.8950,000944,5002,924,551Jun 17 12:00 AM
Bodenstedt MatthiasChief Financial OfficerMay 11 '26Sale20.0213,653273,3331,172,431May 13 12:00 AM
Bodenstedt MatthiasChief Financial OfficerApr 14 '26Sale19.562,42647,4531,186,084Apr 16 12:00 AM
Santos da Silva JorgeChief Executive OfficerApr 13 '26Sale18.2351,873945,6452,924,893Apr 14 12:00 AM
Santos da Silva JorgeChief Executive OfficerApr 10 '26Sale18.4198,1271,806,5182,976,766Apr 14 12:00 AM
Bodenstedt MatthiasChief Financial OfficerApr 10 '26Sale19.511,92537,5571,188,510Apr 10 12:00 AM
Bodenstedt MatthiasChief Financial OfficerApr 09 '26Sale18.9485,8701,626,3781,190,435Apr 10 12:00 AM
BVF PARTNERS L P/ILdirector, 10 percent owner:Mar 31 '26Sale16.793,750,00062,962,5011,039,238Apr 02 12:00 AM
Reich KristianChief Scientific OfficerDec 09 '25Sale14.4372,9081,052,0620Dec 10 12:00 AM
Santos da Silva JorgeChief Executive OfficerDec 09 '25Sale14.4970,0001,014,3002,878,577Dec 10 12:00 AM
Reich KristianChief Scientific OfficerDec 08 '25Sale15.08130,0001,960,40072,908Dec 10 12:00 AM
Santos da Silva JorgeChief Executive OfficerDec 08 '25Sale15.08130,0001,960,4002,948,577Dec 10 12:00 AM
Bodenstedt MatthiasChief Financial OfficerOct 08 '25Buy9.0910,87098,808627,536Oct 09 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR